Naked DNA expressing two isoforms of hepatocyte growth factor induces collateral artery augmentation in a rabbit model of limb ischemia

Gene Therapy

Volumn 17, Issue 12, 2010, Pages 1442-1452

  Pyun, W B ^a   Hahn, W ^b   Kim, D S ^b   Yoo, W S ^b   Lee, S D ^b   Won, J H ^b   Rho, B S ^c   Park, Z Y ^d   Kim, J M ^b   Kim, S ^b  

^a Mokdong Hospital   (South Korea)

^b Seoul National University   (South Korea)

^c Biotechnology Department   (South Korea)

^d Gwangju Institute of Science and Technology (GIST)   (South Korea)

Author keywords

hepatocyte growth factor (HGF); ischemic limb disease; isoform

Indexed keywords

AMINO ACID; COMPLEMENTARY DNA; GENOMIC DNA; NAKED DNA; SCATTER FACTOR; VASCULOTROPIN;

ANGIOGRAPHY; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTERY; ARTICLE; BASE PAIRING; CELL MIGRATION; CONTROLLED STUDY; DOPPLER FLOWMETRY; ENDOTHELIUM CELL; GENE TRANSFER; HUMAN; HUMAN CELL; INTRON; LIMB ISCHEMIA; MOUSE; MYOBLAST; NONHUMAN; PRIORITY JOURNAL; RABBIT; RAT; UMBILICAL VEIN;

ANIMALS; ARTERIES; CELL LINE; CELL MOVEMENT; COLLATERAL CIRCULATION; DISEASE MODELS, ANIMAL; DNA; DNA, COMPLEMENTARY; EXTREMITIES; FEMALE; GENE EXPRESSION; GENE THERAPY; GENE TRANSFER TECHNIQUES; GENETIC ENGINEERING; GENETIC VECTORS; HEPATOCYTE GROWTH FACTOR; HUMANS; INTRONS; ISCHEMIA; MALE; MICE; MICE, INBRED BALB C; PROTEIN ISOFORMS; RABBITS; REGIONAL BLOOD FLOW;

ORYCTOLAGUS CUNICULUS;

EID: 78650029098     PISSN: 09697128     EISSN: 14765462     Source Type: Journal    
DOI: 10.1038/gt.2010.101     Document Type: Article

References (44)

1. Criqui MH, Fronek A, Barrett-Connor E, Klauber MR, Gabriel S, Goodman D. The prevalence of peripheral arterial disease in a defined population. Circulation 1985; 71: 510-515.
2. Michaels J. Second European Consensus Document on Chronic Critical Limb Ichaemia. European journal of vascular surgery 1993; 7: 223.
3. Dormandy J, Mahir M, Ascady G, Balsano F, De Leeuw P, Blombery P et al. Fate of the patient with chronic leg ischaemia. A review article. J Cardiovasc Surg (Torino) 1989; 30: 50-57.
4. Most RS, Sinnock P. The epidemiology of lower extremity amputations in diabetic individuals. Diabetes Care 1983; 6: 87-91.
5. Beard JD. ABC of arterial and venous disease: chronic lower limb ischaemia. Br Med J 2000; 320: 854-857.
6. Hiatt WR. Medical treatment of peripheral arterial disease and claudication. N Engl J Med 2001; 344: 1608-1621.
7. Freedman SB. Clinical trials of gene therapy for atherosclerotic cardiovascular disease. Curr Opin Lipidol 2002; 13: 653-661.
8. Isner JM, Asahara T. Angiogenesis and vasculogenesis as therapeutic strategies for postnatal neovascularization. J Clin Invest 1999; 103: 1231-1236.
9. Miyagawa S, Sawa Y, Taketani S, Kawaguchi N, Nakamura T, Matsuura N et al. Myocardial regeneration therapy for heart failure: hepatocyte growth factor enhances the effect of cellular cardiomyoplasty. Circulation 2002; 105: 2556-2561.
10. Rajagopalan S, Mohler III ER, Lederman RJ, Mendelsohn FO, Saucedo JF, Goldman CK et al. Regional angiogenesis with vascular endothelial growth factor in peripheral arterial disease: a phase II randomized, double-blind, controlled study of adeno-viral delivery of vascular endothelial growth factor 121 in patients with disabling intermittent claudication. Circulation 2003; 108: 1933-1938.
11. Kim HJ, Jang SY, Park JI, Byun J, Kim DI, Do YS et al. Vascular endothelial growth factor-induced angiogenic gene therapy in patients with peripheral artery disease. Exp Mol Med 2004; 36: 336-344.
12. Grines CL, Watkins MW, Mahmarian JJ, Iskandrian AE, Rade JJ, Marrott P et al. A randomized, double-blind, placebo-controlled trial of Ad5FGF-4 gene therapy and its effect on myocardial perfusion in patients with stable angina. J Am Coll Cardiol 2003; 42: 1339-1347.
13. Fortuin FD, Vale P, Losordo DW, Symes J, DeLaria GA, Tyner JJ et al. One-year follow-up of direct myocardial gene transfer of vascular endothelial growth factor-2 using naked plasmid deoxyribonucleic acid by way of thoracotomy in no-option patients. Am J Cardiol 2003; 92: 436-439.
14. Losordo DW, Vale PR, Hendel RC, Milliken CE, Fortuin FD, Cummings N et al. Phase 1/2 placebo-controlled, double-blind, dose-escalating trial of myocardial vascular endothelial growth factor 2 gene transfer by catheter delivery in patients with chronic myocardial ischemia. Circulation 2002; 105: 2012-2018.
15. Morishita R, Aoki M, Hashiya N, Makino H, Yamasaki K, Azuma J et al. Safety evaluation of clinical gene therapy using hepatocyte growth factor to treat peripheral arterial disease. Hypertension 2004; 44: 203-209.
16. Funatsu T, Sawa Y, Ohtake S, Takahashi T, Matsumiya G, Matsuura N et al. Therapeutic angiogenesis in the ischemic canine heart induced by myocardial injection of naked complementary DNA plasmid encoding hepatocyte growth factor. J Thorac Cardiovasc Surg 2002; 124: 1099-1105.
17. Morishita R, Aoki M, Hashiya N, Yamasaki K, Kurinami H, Shimizu S et al. Therapeutic angiogenesis using hepatocyte growth factor (HGF). Curr Gene Ther 2004; 4: 199-206.
18. Van Belle E, Witzenbichler B, Chen D, Silver M, Chang L, Schwall R et al. Potentiated angiogenic effect of scatter factor/ hepatocyte growth factor via induction of vascular endothelial growth factor: the case for paracrine amplification of angio-genesis. Circulation 1998; 97: 381-390.
19. Seki T, Hagiya M, Shimonishi M, Nakamura T, Shimizu S. Organization of the human hepatocyte growth factor-encoding gene. Gene 1991; 102: 213-219.
20. Bell A, Chen Q, DeFrances MC, Michalopoulos GK, Zarnegar R. The five amino acid-deleted isoform of hepatocyte growth factor promotes carcinogenesis in transgenic mice. Oncogene 1999; 18: 887-895.
21. Shima N, Tsuda E, Goto M, Yano K, Hayasaka H, Ueda M et al. Hepatocyte growth factor and its variant with a deletion of five amino acids are distinguishable in their biological activity and tertiary structure. Biochem Biophys Res Commun 1994; 200: 808-815.
22. Ahmet I, Sawa Y, Yamaguchi T, Matsuda H. Gene transfer of hepatocyte growth factor improves angiogenesis and function of chronic ischemic myocardium in canine heart. Ann Thorac Surg 2003; 75: 1283-1287.
23. Jayasankar V, Woo YJ, Bish LT, Pirolli TJ, Chatterjee S, Berry MF et al. Gene transfer of hepatocyte growth factor attenuates postinfarction heart failure. Circulation 2003; 108 (Suppl 1): II230-II236.
24. Jin H, Wyss JM, Yang R, Schwall R. The therapeutic potential of hepatocyte growth factor for myocardial infarction and heart failure. Curr Pharm Des 2004; 10: 2525-2533.
25. Taniyama Y, Morishita R, Aoki M, Nakagami H, Yamamoto K, Yamazaki K et al. Therapeutic angiogenesis induced by human hepatocyte growth factor gene in rat and rabbit hindlimb ischemia models: preclinical study for treatment of peripheral arterial disease. Gene Therapy 2001; 8: 181-189.
26. Koike H, Morishita R, Iguchi S, Aoki M, Matsumoto K, Nakamura T et al. Enhanced angiogenesis and improvement of neuropathy by cotransfection of human hepatocyte growth factor and prostacyclin synthase gene. FASEB J 2003; 17: 779-781.
27. Lee Y, Park EJ, Yu SS, Kim DK, Kim S. Improved expression of vascular endothelial growth factor by naked DNA in mouse skeletal muscles: implication for gene therapy of ischemic diseases. Biochem Biophys Res Commun 2000; 272: 230-235.
28. Carlsson M, Osman NF, Ursell PC, Martin AJ, Saeed M. Quantitative MR measurements of regional and global left ventricular function and strain after intramyocardial transfer of VM202 into infarcted swine myocardium. Am J Physiol Heart Circ Physiol 2008; 295: H522-H532.
29. Saeed M, Martin A, Ursell P, Do L, Bucknor M, Higgins CB et al. MR assessment of myocardial perfusion, viability, and function after intramyocardial transfer of VM202, a new plasmid human hepatocyte growth factor in ischemic swine myocardium. Radiology 2008; 249: 107-118.
30. Cho KR, Choi JS, Hahn W, Kim DS, Park JS, Lee DS et al. Therapeutic angiogenesis using naked DNA expressing two isoforms of the hepatocyte growth factor in a porcine acute myocardial infarction model. Eur J Cardiothorac Surg 2008; 34: 857-863.
31. Kastrup J, Jorgensen E, Ruck A, Tagil K, Glogar D, Ruzyllo W et al. Direct intramyocardial plasmid vascular endothelial growth factor-A165 gene therapy in patients with stable severe angina pectoris A randomized double-blind placebo-controlled study: the Euroinject One trial. J Am Coll Cardiol 2005; 45: 982-988.
32. Vale PR, Losordo DW, Milliken CE, Maysky M, Esakof DD, Symes JF et al. Left ventricular electromechanical mapping to assess efficacy of phVEGF(165) gene transfer for therapeutic angiogenesis in chronic myocardial ischemia. Circulation 2000; 102: 965-974.
33. Baumgartner I, Pieczek A, Manor O, Blair R, Kearney M, Walsh K et al. Constitutive expression of phVEGF165 after intramuscular gene transfer promotes collateral vessel development in patients with critical limb ischemia. Circulation 1998; 97: 1114-1123.
34. Losordo DW, Vale PR, Symes JF, Dunnington CH, Esakof DD, Maysky M et al. Gene therapy for myocardial angiogenesis: initial clinical results with direct myocardial injection of phVEGF165 as sole therapy for myocardial ischemia. Circulation 1998; 98: 2800-2804.
35. Choi JS, Kim KB, Han W, Kim DS, Park JS, Lee JJ et al. Efficacy of therapeutic angiogenesis by intramyocardial injection of pCK-VEGF165 in pigs. Ann Thorac Surg 2006; 82: 679-686.
36. Tomita N, Morishita R, Taniyama Y, Koike H, Aoki M, Shimizu H et al. Angiogenic property of hepatocyte growth factor is dependent on upregulation of essential transcription factor for angiogenesis, ets-1. Circulation 2003; 107: 1411-1417.
37. Taniyama Y, Morishita R, Nakagami H, Moriguchi A, Sakonjo H, Shokei K et al. Potential contribution of a novel antifibrotic factor, hepatocyte growth factor, to prevention of myocardial fibrosis by angiotensin II blockade in cardiomyopathic hamsters. Circulation 2000; 102: 246-252.
38. Kim JM, Jeong JG, Ho SH, Hahn W, Park EJ, Kim S et al. Protection against collagen-induced arthritis by intramuscular gene therapy with an expression plasmid for the interleukin-1 receptor antagonist. Gene Therapy 2003; 10: 1543-1550.
39. Salbach PB, Bruckmann M, Turovets O, Kreuzer J, Kubler W, Walter-Sack I. Heparin-mediated selective release of hepatocyte growth factor in humans. Br J Clin Pharmacol 2000; 50: 221-226.
40. Suzuki J, Yamazaki Y, Li G, Kaziro Y, Koide H. Involvement of Ras and Ral in chemotactic migration of skeletal myoblasts. Mol Cell Biol 2000; 20: 4658-4665.
41. Watt DJ, Karasinski J, Moss J, England MA. Migration of muscle cells. Nature 1994; 368: 406-407.
42. Kim JM, Hahn W. Hybrid hepatocyte growth factor gene having high expression efficiency of two heterotypes of hepatocyte growth factor. US2005/0079581 A1.
43. Merkulova-Rainon T, England P, Ding S, Demerens C, Tobelem G. The N-terminal domain of hepatocyte growth factor inhibits the angiogenic behavior of endothelial cells independently from binding to the c-met receptor. J Biol Chem 2003; 278: 37400-37408.
44. Tsurumi Y, Takeshita S, Chen D, Kearney M, Rossow ST, Passeri J et al. Direct intramuscular gene transfer of naked DNA encoding vascular endothelial growth factor augments collateral development and tissue perfusion. Circulation 1996; 94: 3281-3290.